Having priced its shares at the top of its range, UChicago spinout Pyxis Oncology suffered a drop on the first day of trading.

Pyxis Oncology, a US-based cancer therapy developer spun out of University of Chicago (UChicago), issued 10.5 million shares priced at $16 to raise $168m in an upsized initial public offering on Friday.

Although the price marks the top end of Pyxis’ range and shares opened at $18.88, they crashed to $13.20 by the end of the first day of trading on the Nasdaq Global Select Market, where Pyxis is now listed under PYXS.

Founded in 2018, Pyxis…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn